tenk.fyi

NEOGEN CORP

NEOGNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$870.4M

2.7% YoY

Net Income

-$7.9M

99.3% YoY

EPS

$-0.04

99.2% YoY

Cash

$185.5M

43.8% YoY

FY 2026 · As of 2026-05-31

No recent insider transactions found.

ProShowing last 90 days. Full 12+ month history available on Pro.
Upgrade